Updating the HRSA-Supported Women's Preventive Services Guidelines, 95148-95150 [2016-31129]
Download as PDF
95148
Federal Register / Vol. 81, No. 248 / Tuesday, December 27, 2016 / Notices
Abstract: Currently HRSA is cleared
to use the National Institutes of Health’s
(NIH) Biographical Sketch and Public
Health Service (PHS) Inclusion
Enrollment forms (0925–0001) for
HRSA’s SF424 Research & Related
(R&R) application package research
grants. However, both of these
documents contain NIH-specific
references. To use the forms, HRSA
plans to remove the NIH-specific
references and obtain its own OMB
control number for the collection of this
information.
The current Statement of
Appointment (form PHS–2271) is also
tailored to NIH programs. HRSA plans
to remove references to NIH and where
appropriate replace them with
references to HRSA for use in the SF424
R&R application package.
Need and Proposed Use of the
Information: Currently, there are two
Bureaus within HRSA, the Maternal and
Child Health Bureau (MCHB) and the
Bureau of Health Workforce (BHW), that
use the Biographical Sketch. In addition
to the Biographical Sketch, MCHB also
uses the PHS Inclusion Enrollment
form, and BHW uses the Statement of
Appointment form as required elements
of the SF424 Research & Related
application package. These Bureaus
plan to modify these forms in slightly
different ways to meet the needs of their
own research and training grant
programs.
In MCHB’s research grant programs,
the modified Biographical Sketch form
will be used by applicants to summarize
the qualifications of key personnel on
their proposed research team; the grant
reviewers will use this information to
assess the capabilities of the research
team to carry out the research project.
MCHB’s modified PHS Inclusion
Enrollment form will be used by
applicants to summarize their expected
population of research study
participants at the time of submission of
their proposal; it will also be used for
Enrollment Reporting during the annual
Noncompeting Continuation Award.
Monitoring Inclusion Enrollment is one
important component of ensuring
statistically meaningful demographics
(race, ethnicity, and gender) among
research study participants in MCHB’s
research grant portfolio. MCHB does not
use the Statement of Appointment form,
as it does not pertain to the MCHB
research program.
Similarly, in BHW the modified
Biographical Sketch form will be used
by applicants to summarize the
qualifications of key personnel
proposed as project staff; the grant
reviewers will use this information to
assess the capabilities of the applicant
organization to carry out the proposed
project. The modified Statement of
Appointment form is used to document
the appointment of individuals
supported by the award to applicable
institutional research and training
programs. BHW does not use the PHS
Inclusion Enrollment form, as it does
not pertain to the BHW training and
research programs.
Likely Respondents: Respondents are
applicants to HRSA’s research programs
in MCHB and research and training
programs in BHW.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and be able to respond to a
collection of information; to search data
sources; to complete and review the
collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this Information
Collection Request are summarized in
the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Total ..............................................................................
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Biographical Sketch for MCHB research grant applicants ..
PHS Inclusion Enrollment form for MCHB research grant
applications .......................................................................
Biographical Sketch for BHW training and research grant
applicants .........................................................................
Statement of Appointment form for BHW training grantees
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–31080 Filed 12–23–16; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
20:45 Dec 23, 2016
Jkt 241001
Number of
responses per
respondent
Total burden
hours
5
1000
2
2000
200
1
200
.5
100
1000
800
5
7
5000
5600
2
.5
10,000
2,800
2200
........................
11,800
........................
14,900
Health Resources and Services
Administration
Updating the HRSA-Supported
Women’s Preventive Services
Guidelines
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
Effective December 20, 2016,
the Health Resources and Services
Administration (HRSA) updated the
HRSA-supported Women’s Preventive
SUMMARY:
Frm 00051
Average
burden per
response
(in hours)
200
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Total
responses
Fmt 4703
Sfmt 4703
Services Guidelines for purposes of
health insurance coverage for preventive
services that address health needs
specific to women based on clinical
recommendations from the Women’s
Preventive Services Initiative. This
notice serves as an announcement of the
decision to update the guidelines as
listed below. Please see https://
www.hrsa.gov/womensguidelines2016
for additional information.
FOR FURTHER INFORMATION CONTACT:
HRSA, Maternal and Child Health
Bureau at email: wellwomancare@
hrsa.gov.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\27DEN1.SGM
27DEN1
Federal Register / Vol. 81, No. 248 / Tuesday, December 27, 2016 / Notices
Breast Cancer Screening for AverageRisk Women
The Women’s Preventive Services
Initiative recommends that average-risk
women initiate mammography
screening no earlier than age 40 and no
later than age 50. Screening
mammography should occur at least
biennially and as frequently as
annually. Screening should continue
through at least age 74 and age alone
should not be the basis to discontinue
screening.
These screening recommendations are
for women at average risk of breast
cancer. Women at increased risk should
also undergo periodic mammography
screening, however, recommendations
for additional services are beyond the
scope of this recommendation.
Breastfeeding Services and Supplies
The Women’s Preventive Services
Initiative recommends comprehensive
lactation support services (including
counseling, education, and
breastfeeding equipment and supplies)
during the antenatal, perinatal, and
postpartum periods to ensure the
successful initiation and maintenance of
breastfeeding.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Screening for Cervical Cancer
The Women’s Preventive Services
Initiative recommends cervical cancer
screening for average-risk women aged
21 to 65 years. For women aged 21 to
29 years, the Women’s Preventive
Services Initiative recommends cervical
cancer screening using cervical cytology
(Pap test) every 3 years. Cotesting with
cytology and human papillomavirus
testing is not recommended for women
younger than 30 years. Women aged 30
to 65 years should be screened with
cytology and human papillomavirus
testing every 5 years or cytology alone
every 3 years. Women who are at
average risk should not be screened
more than once every 3 years.
Contraception
The Women’s Preventive Services
Initiative recommends that adolescent
and adult women have access to the full
range of female-controlled
contraceptives to prevent unintended
pregnancy and improve birth outcomes.
Contraceptive care should include
contraceptive counseling, initiation of
contraceptive use, and follow-up care
(e.g., management, and evaluation as
well as changes to and removal or
discontinuation of the contraceptive
method). The Women’s Preventive
Services Initiative recommends that the
full range of female-controlled U.S.
Food and Drug Administrationapproved contraceptive methods,
VerDate Sep<11>2014
20:45 Dec 23, 2016
Jkt 241001
95149
effective family planning practices, and
sterilization procedures be available as
part of contraceptive care.
The full range of contraceptive
methods for women currently identified
by the U.S. Food and Drug
Administration include: (1) Sterilization
surgery for women, (2) surgical
sterilization via implant for women, (3)
implantable rods, (4) copper
intrauterine devices, (5) intrauterine
devices with progestin (all durations
and doses), (6) the shot or injection, (7)
oral contraceptives (combined pill), 8)
oral contraceptives (progestin only,
and), (9) oral contraceptives (extended
or continuous use), (10) the
contraceptive patch, (11) vaginal
contraceptive rings, (12) diaphragms,
(13) contraceptive sponges, (14) cervical
caps, (15) female condoms, (16)
spermicides, and (17) emergency
contraception (levonorgestrel), and (18)
emergency contraception (ulipristal
acetate), and additional methods as
identified by the FDA. Additionally,
instruction in fertility awareness-based
methods, including the lactation
amenorrhea method, although less
effective, should be provided for women
desiring an alternative method.
and women with an increased risk of
HIV infection.
Screening for HIV is recommended for
all pregnant women upon initiation of
prenatal care with retesting during
pregnancy based on risk factors. Rapid
HIV testing is recommended for
pregnant women who present in active
labor with an undocumented HIV status.
Screening during pregnancy enables
prevention of vertical transmission.
Screening for Gestational Diabetes
Mellitus
Screening for Human
Immunodeficiency Virus Infection
Counseling for Sexually Transmitted
Infections
The Women’s Preventive Services
Initiative recommends directed
behavioral counseling by a health care
provider or other appropriately trained
individual for sexually active adolescent
and adult women at an increased risk
for sexually transmitted infections
(STIs).
The Women’s Preventive Services
Initiative recommends that health care
providers use a woman’s sexual history
and risk factors to help identify those at
an increased risk of STIs. Risk factors
may include age younger than 25, a
recent history of an STI, a new sex
partner, multiple partners, a partner
with concurrent partners, a partner with
an STI, and a lack of or inconsistent
condom use. For adolescents and
women not identified as high risk,
counseling to reduce the risk of STIs
should be considered, as determined by
clinical judgement.
The Women’s Preventive Services
Initiative recommends prevention
education and risk assessment for
human immunodeficiency virus (HIV)
infection in adolescents and women at
least annually throughout the lifespan.
All women should be tested for HIV at
least once during their lifetime.
Additional screening should be based
on risk, and screening annually or more
often may be appropriate for adolescents
Well-Woman Preventive Visits
The Women’s Preventive Services
Initiative recommends that women
receive at least one preventive care visit
per year beginning in adolescence and
continuing across the lifespan to ensure
that the recommended preventive
services including preconception, and
many services necessary for prenatal
and interconception care are obtained.
The primary purpose of these visits
The Women’s Preventive Services
Initiative recommends screening
pregnant women for gestational diabetes
mellitus after 24 weeks of gestation
(preferably between 24 and 28 weeks of
gestation) in order to prevent adverse
birth outcomes. Screening with a 50-g
oral glucose challenge test (followed by
a 3-hour 100-g oral glucose tolerance
test if results on the initial oral glucose
challenge test are abnormal) is preferred
because of its high sensitivity and
specificity.
The Women’s Preventive Services
Initiative suggests that women with risk
factors for diabetes mellitus be screened
for preexisting diabetes before 24 weeks
of gestation—ideally at the first prenatal
visit, based on current clinical best
practices.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Screening for Interpersonal and
Domestic Violence
The Women’s Preventive Services
Initiative recommends screening
adolescents and women for
interpersonal and domestic violence, at
least annually, and, when needed,
providing or referring for initial
intervention services. Interpersonal and
domestic violence includes physical
violence, sexual violence, stalking and
psychological aggression (including
coercion), reproductive coercion,
neglect, and the threat of violence,
abuse, or both. Intervention services
include, but are not limited to,
counseling, education, harm reduction
strategies, and referral to appropriate
supportive services.
E:\FR\FM\27DEN1.SGM
27DEN1
asabaliauskas on DSK3SPTVN1PROD with NOTICES
95150
Federal Register / Vol. 81, No. 248 / Tuesday, December 27, 2016 / Notices
should be the delivery and coordination
of recommended preventive services as
determined by age and risk factors.
The HRSA-supported Women’s
Preventive Services Guidelines were
originally established in 2011 based on
recommendations from a Department of
Health and Human Services’
commissioned study by the Institute of
Medicine (IOM), now known as the
National Academy of Medicine (NAM).
Since then, there have been
advancements in science and gaps
identified in the existing guidelines,
including a greater emphasis on
practice-based clinical considerations.
To address these, HRSA awarded a 5year cooperative agreement in March
2016 to convene a coalition of clinician,
academic, and consumer-focused health
professional organizations and conduct
a scientifically rigorous review to
develop recommendations for updated
Women’s Preventive Services
Guidelines in accordance with the
model created by the NAM Clinical
Practice Guidelines We Can Trust. The
American College of Obstetricians and
Gynecologists was awarded the
cooperative agreement and formed an
expert panel called the Women’s
Preventive Services Initiative.
Under section 2713 of the Public
Health Service Act, non-grandfathered
group health plans and issuers of nongrandfathered group and individual
health insurance coverage are required
to cover specified preventive services
without a copayment, coinsurance,
deductible, or other cost sharing,
including preventive care and
screenings for women as provided for in
comprehensive guidelines supported by
HRSA for this purpose. Nongrandfathered plans and coverage
(generally, plans or policies created or
sold after March 23, 2010, or older plans
or policies that have been changed in
certain ways since that date) are
required to provide coverage without
cost sharing consistent with these
guidelines beginning with the first plan
year (in the individual market, policy
year) that begins on or after December
20, 2017.
The guidelines concerning
contraceptive methods and counseling
do not apply to women who are
participants or beneficiaries in group
health plans sponsored by religious
employers. Effective August 1, 2013, a
religious employer is defined as an
employer that is organized and operates
as a non-profit entity and is referred to
in section 6033(a)(3)(A)(i) or (iii) of the
Internal Revenue Code. HRSA notes
that, as of August 1, 2013, group health
plans established or maintained by
religious employers (and group health
VerDate Sep<11>2014
20:45 Dec 23, 2016
Jkt 241001
insurance coverage provided in
connection with such plans) are exempt
from the requirement to cover
contraceptive services under section
2713 of the Public Health Service Act,
as incorporated into the Employee
Retirement Income Security Act and the
Internal Revenue Code. HRSA also notes
that, as of January 1, 2014,
accommodations are available to group
health plans established or maintained
by certain eligible organizations (and
group health insurance coverage
provided in connection with such
plans), as well as student health
insurance coverage arranged by eligible
organizations, with respect to the
contraceptive coverage requirement. See
Coverage of Certain Preventive Services
Under the Affordable Care Act (78 FR
39870, July 2, 2013).
James Macrae,
Acting Administrator.
[FR Doc. 2016–31129 Filed 12–23–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
Announcement of Updated
Requirements and Registration for
‘‘The Simple Extensible Sampling Tool
Challenge’’
Office of Inspector General
(OIG), HHS.
AGENCY:
ACTION:
Notice.
On September 29, 2016, OIG
announced ‘‘The Simple Extensible
Sampling Tool Challenge’’. This notice
serves as an update to the original
notice which stated that upon receipt of
an updated submission the previous
submission would be excluded in its
entirety from the competition. This
updated notice removes this restriction
for entries from teams that have been
previously identified as finalists. Any
finalist may update their entry without
losing their finalist designation. Updates
from the finalists will be accepted until
5:00 p.m. EST on the fourteenth day
after the fifth finalist has been identified
or May 15, 2017, 5:00 p.m. EST,
whichever comes first. The newest entry
from each team will be used for all
judging purposes unless otherwise
requested by the team. Other than the
above change, all rules and
requirements outlined in the September
29, 2016, Federal Register notice remain
in effect.
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Dated: December 21, 2016.
Daniel R. Levinson,
Inspector General.
[FR Doc. 2016–31182 Filed 12–23–16; 8:45 am]
BILLING CODE 4152–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
Council of Councils.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov).
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4), and 552b(c)(6), Title 5
U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Council of Councils.
Open: January 27, 2017.
Time: 8:15 a.m. to 11:30 a.m.
Agenda: Call to Order and Introductions;
Announcements and Updates; Tracking
Utility of Common Fund Data Sets; Small
Molecules from the Human Microbiota;
Invited Speaker; NIH Update; Discussion;
2017 Biennial Advisory Council Report—
Compliance with the NIH Policy on the
Inclusion of Women and Minorities in
Clinical Research.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Closed: January 27, 2017.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: Review of grant applications.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Open: January 27, 2017.
E:\FR\FM\27DEN1.SGM
27DEN1
Agencies
[Federal Register Volume 81, Number 248 (Tuesday, December 27, 2016)]
[Notices]
[Pages 95148-95150]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-31129]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Updating the HRSA-Supported Women's Preventive Services
Guidelines
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Effective December 20, 2016, the Health Resources and Services
Administration (HRSA) updated the HRSA-supported Women's Preventive
Services Guidelines for purposes of health insurance coverage for
preventive services that address health needs specific to women based
on clinical recommendations from the Women's Preventive Services
Initiative. This notice serves as an announcement of the decision to
update the guidelines as listed below. Please see https://www.hrsa.gov/womensguidelines2016 for additional information.
FOR FURTHER INFORMATION CONTACT: HRSA, Maternal and Child Health Bureau
at email: wellwomancare@hrsa.gov.
SUPPLEMENTARY INFORMATION:
[[Page 95149]]
Breast Cancer Screening for Average-Risk Women
The Women's Preventive Services Initiative recommends that average-
risk women initiate mammography screening no earlier than age 40 and no
later than age 50. Screening mammography should occur at least
biennially and as frequently as annually. Screening should continue
through at least age 74 and age alone should not be the basis to
discontinue screening.
These screening recommendations are for women at average risk of
breast cancer. Women at increased risk should also undergo periodic
mammography screening, however, recommendations for additional services
are beyond the scope of this recommendation.
Breastfeeding Services and Supplies
The Women's Preventive Services Initiative recommends comprehensive
lactation support services (including counseling, education, and
breastfeeding equipment and supplies) during the antenatal, perinatal,
and postpartum periods to ensure the successful initiation and
maintenance of breastfeeding.
Screening for Cervical Cancer
The Women's Preventive Services Initiative recommends cervical
cancer screening for average-risk women aged 21 to 65 years. For women
aged 21 to 29 years, the Women's Preventive Services Initiative
recommends cervical cancer screening using cervical cytology (Pap test)
every 3 years. Cotesting with cytology and human papillomavirus testing
is not recommended for women younger than 30 years. Women aged 30 to 65
years should be screened with cytology and human papillomavirus testing
every 5 years or cytology alone every 3 years. Women who are at average
risk should not be screened more than once every 3 years.
Contraception
The Women's Preventive Services Initiative recommends that
adolescent and adult women have access to the full range of female-
controlled contraceptives to prevent unintended pregnancy and improve
birth outcomes. Contraceptive care should include contraceptive
counseling, initiation of contraceptive use, and follow-up care (e.g.,
management, and evaluation as well as changes to and removal or
discontinuation of the contraceptive method). The Women's Preventive
Services Initiative recommends that the full range of female-controlled
U.S. Food and Drug Administration-approved contraceptive methods,
effective family planning practices, and sterilization procedures be
available as part of contraceptive care.
The full range of contraceptive methods for women currently
identified by the U.S. Food and Drug Administration include: (1)
Sterilization surgery for women, (2) surgical sterilization via implant
for women, (3) implantable rods, (4) copper intrauterine devices, (5)
intrauterine devices with progestin (all durations and doses), (6) the
shot or injection, (7) oral contraceptives (combined pill), 8) oral
contraceptives (progestin only, and), (9) oral contraceptives (extended
or continuous use), (10) the contraceptive patch, (11) vaginal
contraceptive rings, (12) diaphragms, (13) contraceptive sponges, (14)
cervical caps, (15) female condoms, (16) spermicides, and (17)
emergency contraception (levonorgestrel), and (18) emergency
contraception (ulipristal acetate), and additional methods as
identified by the FDA. Additionally, instruction in fertility
awareness-based methods, including the lactation amenorrhea method,
although less effective, should be provided for women desiring an
alternative method.
Screening for Gestational Diabetes Mellitus
The Women's Preventive Services Initiative recommends screening
pregnant women for gestational diabetes mellitus after 24 weeks of
gestation (preferably between 24 and 28 weeks of gestation) in order to
prevent adverse birth outcomes. Screening with a 50-g oral glucose
challenge test (followed by a 3-hour 100-g oral glucose tolerance test
if results on the initial oral glucose challenge test are abnormal) is
preferred because of its high sensitivity and specificity.
The Women's Preventive Services Initiative suggests that women with
risk factors for diabetes mellitus be screened for preexisting diabetes
before 24 weeks of gestation--ideally at the first prenatal visit,
based on current clinical best practices.
Screening for Human Immunodeficiency Virus Infection
The Women's Preventive Services Initiative recommends prevention
education and risk assessment for human immunodeficiency virus (HIV)
infection in adolescents and women at least annually throughout the
lifespan. All women should be tested for HIV at least once during their
lifetime. Additional screening should be based on risk, and screening
annually or more often may be appropriate for adolescents and women
with an increased risk of HIV infection.
Screening for HIV is recommended for all pregnant women upon
initiation of prenatal care with retesting during pregnancy based on
risk factors. Rapid HIV testing is recommended for pregnant women who
present in active labor with an undocumented HIV status. Screening
during pregnancy enables prevention of vertical transmission.
Screening for Interpersonal and Domestic Violence
The Women's Preventive Services Initiative recommends screening
adolescents and women for interpersonal and domestic violence, at least
annually, and, when needed, providing or referring for initial
intervention services. Interpersonal and domestic violence includes
physical violence, sexual violence, stalking and psychological
aggression (including coercion), reproductive coercion, neglect, and
the threat of violence, abuse, or both. Intervention services include,
but are not limited to, counseling, education, harm reduction
strategies, and referral to appropriate supportive services.
Counseling for Sexually Transmitted Infections
The Women's Preventive Services Initiative recommends directed
behavioral counseling by a health care provider or other appropriately
trained individual for sexually active adolescent and adult women at an
increased risk for sexually transmitted infections (STIs).
The Women's Preventive Services Initiative recommends that health
care providers use a woman's sexual history and risk factors to help
identify those at an increased risk of STIs. Risk factors may include
age younger than 25, a recent history of an STI, a new sex partner,
multiple partners, a partner with concurrent partners, a partner with
an STI, and a lack of or inconsistent condom use. For adolescents and
women not identified as high risk, counseling to reduce the risk of
STIs should be considered, as determined by clinical judgement.
Well-Woman Preventive Visits
The Women's Preventive Services Initiative recommends that women
receive at least one preventive care visit per year beginning in
adolescence and continuing across the lifespan to ensure that the
recommended preventive services including preconception, and many
services necessary for prenatal and interconception care are obtained.
The primary purpose of these visits
[[Page 95150]]
should be the delivery and coordination of recommended preventive
services as determined by age and risk factors.
The HRSA-supported Women's Preventive Services Guidelines were
originally established in 2011 based on recommendations from a
Department of Health and Human Services' commissioned study by the
Institute of Medicine (IOM), now known as the National Academy of
Medicine (NAM). Since then, there have been advancements in science and
gaps identified in the existing guidelines, including a greater
emphasis on practice-based clinical considerations. To address these,
HRSA awarded a 5-year cooperative agreement in March 2016 to convene a
coalition of clinician, academic, and consumer-focused health
professional organizations and conduct a scientifically rigorous review
to develop recommendations for updated Women's Preventive Services
Guidelines in accordance with the model created by the NAM Clinical
Practice Guidelines We Can Trust. The American College of Obstetricians
and Gynecologists was awarded the cooperative agreement and formed an
expert panel called the Women's Preventive Services Initiative.
Under section 2713 of the Public Health Service Act, non-
grandfathered group health plans and issuers of non-grandfathered group
and individual health insurance coverage are required to cover
specified preventive services without a copayment, coinsurance,
deductible, or other cost sharing, including preventive care and
screenings for women as provided for in comprehensive guidelines
supported by HRSA for this purpose. Non-grandfathered plans and
coverage (generally, plans or policies created or sold after March 23,
2010, or older plans or policies that have been changed in certain ways
since that date) are required to provide coverage without cost sharing
consistent with these guidelines beginning with the first plan year (in
the individual market, policy year) that begins on or after December
20, 2017.
The guidelines concerning contraceptive methods and counseling do
not apply to women who are participants or beneficiaries in group
health plans sponsored by religious employers. Effective August 1,
2013, a religious employer is defined as an employer that is organized
and operates as a non-profit entity and is referred to in section
6033(a)(3)(A)(i) or (iii) of the Internal Revenue Code. HRSA notes
that, as of August 1, 2013, group health plans established or
maintained by religious employers (and group health insurance coverage
provided in connection with such plans) are exempt from the requirement
to cover contraceptive services under section 2713 of the Public Health
Service Act, as incorporated into the Employee Retirement Income
Security Act and the Internal Revenue Code. HRSA also notes that, as of
January 1, 2014, accommodations are available to group health plans
established or maintained by certain eligible organizations (and group
health insurance coverage provided in connection with such plans), as
well as student health insurance coverage arranged by eligible
organizations, with respect to the contraceptive coverage requirement.
See Coverage of Certain Preventive Services Under the Affordable Care
Act (78 FR 39870, July 2, 2013).
James Macrae,
Acting Administrator.
[FR Doc. 2016-31129 Filed 12-23-16; 8:45 am]
BILLING CODE 4165-15-P